AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01000480 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Description: Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
Study NCT02561702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
Study NCT01413542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: enalaprilat (ACE inhibitor)
Description: intra-brachial artery(0.33 µg/min per 100 mL forearm volume)
Study NCT01413542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon-like peptide 1
Description: intra-brachial artery (0.45-3.60 pmol/min)
Study NCT02827721 — intervention group
Intervention type: DEVICE
Intervention: multiple breath washout test
Study NCT03423641 — intervention group
Intervention type: DRUG
Intervention: Direct Acting Antivirals
Description: The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
Study NCT00270790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Amifostine will be given at dose of 500 mg IV within one hour before radiation
Study NCT00270790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
Study NCT01413542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: brain natriuretic peptide
Description: Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)
Study NCT02279121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolock
Description: At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
Study NCT02279121 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: saline solution
Description: At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
Study NCT01556802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocicline
Description: Minocicline 100mg oral twice a day for 5 days
Study NCT01556802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills with vegetable fibers one pill oral twice a day for five days
Study NCT02827721 — intervention group
Intervention type: DEVICE
Intervention: body plethysmography
Study NCT00270790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
Study NCT00270790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
Study NCT00332007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonabersat
Description: two tablets once daily
Study NCT00332007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two tablets once daily
Study NCT01919593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate in 70% alcohol
Description: skin preparation before venipuncture for blood culture in even month
Study NCT01919593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10%povidone iodine
Description: skin preparation before venipuncture for blood culture in odd month
Study NCT04655378 — intervention group
Intervention type: OTHER
Intervention: Mass Sepctrometry
Description: Mass spectrometry (LC/MS) of purified immunoglobulins
Study NCT02171377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: group 2 : quadricipital electrical stimulation
Description: bilateral quadricipital electrical stimulation 5 sessions a week, (6 - 8 weeks)
Study NCT02171377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary rehabilitation
Description: exercise training, 3 to 5 times per week, 8 weeks
Study NCT02668289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: consent
Description: At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.
Study NCT02668289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Screening
Description: At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.
Study NCT02668289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Xray
Description: each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.
Study NCT02668289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PVS Impressions
Description: PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.
Study NCT02668289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Photographs
Description: Intraoral photographs will also be taken and subsequent study visits will be planned.
Study NCT02668289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CBCT
Description: The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT and follow-up at 14 week CBCT. These CBCT's will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.
Study NCT02668289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anesthesia
Description: After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.
Study NCT02668289 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Extraction
Description: After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.
Study NCT02668289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical measurements
Description: Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
Study NCT02832570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 100mg single oral dose
Description: Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
Study NCT02832570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Oral intake single dose
Description: Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
Study NCT03134326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: R1-25 and R2-25 Pulse Oximeter Sensor
Study NCT02171377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: muscular electrical stimulation
Description: Bilateral quadricipital electrical stimulation 30 min, 5 times per week, 8 weeks,in addition to pulmonary rehabilitation
Study NCT02171377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary rehabilitation
Description: exercise training, 45 min, 3 to 5 times per week, 8 weeks
Study NCT01207791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: screening
Description: Brief screening to assess eligibility and collect minimal baseline data
Study NCT01207791 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: screening
Description: Brief screening to assess eligibility and collect minimal baseline data
Study NCT01207791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: screening
Description: Brief screening to assess eligibility and collect minimal baseline data
Study NCT01207791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment
Description: comprehensive substance use assessment
Study NCT01207791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: assessment
Description: comprehensive substance use assessment
Study NCT01207791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: referral
Description: referral to treatment if indicated or requested
Study NCT01207791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: referral
Description: referral to treatment if indicated or requested
Study NCT01207791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: 30-minute brief intervention session in ED
Study NCT01207791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: booster sessions
Description: two 15-minute booster counseling sessions conducted by telephone
Study NCT01893710 — intervention group
Intervention type: PROCEDURE
Intervention: biopsy sampling
Description: Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial.
Study NCT02442050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: del Nido solution
Description: 1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
Study NCT00156052 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional whole breast radiation schedule
Study NCT00156052 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated whole breast radiation schedule
Study NCT03428802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03428802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02130232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Study NCT02442050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood-based cardioplegia
Description: An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
Study NCT02130232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study NCT03296098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Description: Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
Study NCT04384614 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Test PCR
Description: Viral load (COVID+) testing by PCR
Study NCT04384614 — intervention group
Intervention type: GENETIC
Intervention: TDR
Description: IDR and blood sampling for testing DNA Cheque
Study NCT04384614 — intervention group
Intervention type: OTHER
Intervention: Clinical Examination
Description: COVID 19 symptoms and Physical Examination
Study NCT00805584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
Study NCT03991585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical Contour Regulation Facilitation (MCRF)
Description: MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.
Study NCT02160288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin-A
Description: 100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
Study NCT02160288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Dispensed in a 5 cc syringe
Study NCT02903290 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait
Study NCT02903290 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: walking track GAITRite,manual dynamometer, and treadmill
Study NCT01916993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854 50 mg capsule
Study NCT02561702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Description: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
Study NCT02410018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCL 503 (uterine artery embolization)
Description: Transcatheter embolization of the uterine artery(ies) using an embolic agent.
Study NCT02935998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
Study NCT01820182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capsule endoscopies
Description: Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
Study NCT02781623 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Study NCT01924676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
Study NCT01924676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
Study NCT01924676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
Study NCT02727296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: General anesthesia with sevoflurane
Study NCT02727296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: General anesthesia with propofol
Study NCT02928861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
Study NCT02750514 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
Study NCT02750514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
Study NCT03886831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT543
Description: PRT543 will be administered orally
Study NCT00039741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)
Description: Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor
Study NCT02750514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study NCT02750514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Study NCT02750514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02750514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified dose on specified days
Study NCT02142088 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GlySure Intravascular Continuous glucose monitoring sensor
Description: Comparator device is an iSTAT device from Abbott Diagnostics
Study NCT01823289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
Study NCT01306292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: dose of 4.8 mL administered intravenously one time
Study NCT01306292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
Study NCT01554748 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total joint arthroplasty
Study NCT02213029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epelsiban
Description: White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or >150mg
Study NCT02213029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to off white oral placebo tablets to match 5mg epelsiban
Study NCT02213029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
Study NCT02213029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cylcen (21)® tablet
Description: White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson
Study NCT05809089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula (HFNC)
Description: High-flow nasal cannula device was utilized. Humidifier temperature was set at 37°C via large-bore bi-nasal prongs, and inspired oxygen (FiO2) was adjusted to maintain oxygen saturation by pulse oximetry (SpO2) ≥ 90%.The flow was initially set at 10 L/min and titrated upward in 5 L/min steps until patients experienced discomfort.~Patient will be evaluated every 8 hours and discontinued the device for eating, drinking and coughing up secretion and returned back to the device for 72 hours.
Study NCT05809089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Description: Patients initiated NIV; Inspiratory positive airway pressure (IPAP) was initiated at 10-12 cmH2O, and expiratory positive airway pressure (EPAP) started at 4-5 cmH2O. FIO2 was adjusted to maintain SpO2 ≥ 90%. The same protocol as done in HFNC, patient will be evaluated every 8 hours and discontinued the device and returned back to the device for re- evaluation within 72 hours
Study NCT02814656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
Study NCT02814656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
Study NCT03431870 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Trans-esophageal echocardiography
Description: Perform a trans-esophageal echocardiography before and after anesthesia.
Study NCT01249001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Aprepitant
Description: Subject will receive an oral suspension containing 125mg of Aprepitant